These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24038291)

  • 1. Toxic epitheliopathy from a single application of preservative free oxybuprocaine (0.4%) in a patient with Sjogren's syndrome.
    Ansari H; Weinberg L; Spencer N
    BMJ Case Rep; 2013 Sep; 2013():. PubMed ID: 24038291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinous iritis due to oxybuprocaine.
    Haddad R
    Br J Ophthalmol; 1989 Jan; 73(1):76-7. PubMed ID: 2920158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxybuprocaine keratopathy: a preventable disease.
    Penna EP; Tabbara KF
    Br J Ophthalmol; 1986 Mar; 70(3):202-4. PubMed ID: 3954977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sterile corneal perforation after cataract surgery in Sjögren's syndrome.
    Cohen KL
    Br J Ophthalmol; 1982 Mar; 66(3):179-82. PubMed ID: 7066269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of spontaneous corneal perforation secondary to undiagnosed Sjögren's syndrome using regenerating agent and autologous serum eye drops.
    Tzamalis A; Matsou A; Anastasopoulos E; Ziakas N
    Eur J Ophthalmol; 2021 Jan; 31(1):NP17-NP21. PubMed ID: 31137968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Degree and duration of corneal anesthesia after topical application of 0.4% oxybuprocaine hydrochloride ophthalmic solution in ophthalmically normal dogs.
    Douet JY; Michel J; Regnier A
    Am J Vet Res; 2013 Oct; 74(10):1321-6. PubMed ID: 24066916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maxitrol-induced corneal melts after routine cataract surgery in rheumatology patients.
    Lockington D; Sharma R; Mantry S; Ramaesh K
    Clin Exp Ophthalmol; 2015 Mar; 43(2):188-9. PubMed ID: 24995710
    [No Abstract]   [Full Text] [Related]  

  • 8. [Current treatments of xerophthalmia in Sjögren's syndrome].
    Baudouin C; Pisella PJ; Brignole F
    Rev Med Interne; 2004 May; 25(5):376-82. PubMed ID: 15110955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corneal thickness values before and after oxybuprocaine 0.4% eye drops.
    Asensio I; Rahhal SM; Alonso L; Palanca-Sanfrancisco JM; Sanchis-Gimeno JA
    Cornea; 2003 Aug; 22(6):527-32. PubMed ID: 12883345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxic keratopathy associated with abuse of low-dose anesthetic: a case report.
    Chen HT; Chen KH; Hsu WM
    Cornea; 2004 Jul; 23(5):527-9. PubMed ID: 15220742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome.
    Yokoi N; Sonomura Y; Kato H; Komuro A; Kinoshita S
    Eye (Lond); 2015 Sep; 29(9):1204-12. PubMed ID: 26160526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Particularly rapid appearance of a severe toxic keratopathy caused by oxybuprocaine].
    Jallet G; Cleirens S; Girard E; Béchetoille A
    Bull Soc Ophtalmol Fr; 1980; 80(4-5):385-7. PubMed ID: 7460172
    [No Abstract]   [Full Text] [Related]  

  • 13. Recent advances in the management of ocular complications of Sjögren's syndrome.
    Samarkos M; Moutsopoulos HM
    Curr Allergy Asthma Rep; 2005 Jul; 5(4):327-32. PubMed ID: 15967078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal vasculitis associated with autoantibodies of primary Sjögren's syndrome after cataract surgery.
    Lim BS; Kim KS; Kwok SK; Lee WK
    Clin Exp Optom; 2016 Jan; 99(1):87-9. PubMed ID: 26875858
    [No Abstract]   [Full Text] [Related]  

  • 15. [Oxybuprocaine drops and eyedrops should not be given to patientson prescription].
    Cruysberg JR
    Ned Tijdschr Geneeskd; 1990 Sep; 134(39):1910. PubMed ID: 2215773
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome.
    Shah M; Edman MC; Reddy Janga S; Yarber F; Meng Z; Klinngam W; Bushman J; Ma T; Liu S; Louie S; Mehta A; Ding C; MacKay JA; Hamm-Alvarez SF
    Invest Ophthalmol Vis Sci; 2017 Jan; 58(1):372-385. PubMed ID: 28122086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degree of corneal anaesthesia after topical application of 0.4% oxybuprocaine hydrochloride and 0.5% proparacaine hydrochloride ophthalmic solution in clinically normal cattle.
    Little WB; Jean GS; Sithole F; Little E; Jean KY
    Aust Vet J; 2016 Jun; 94(6):181-5. PubMed ID: 27237118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corneal perforation in undiagnosed Sjögren's syndrome following topical NSAID and steroid drops post routine cataract extraction.
    Murtagh P; Comer R; Fahy G
    BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30042108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological investigations following an adverse reaction to oxybuprocaine eye drops.
    Sewell WA; Croucher JJ; Bird AG
    Br J Ophthalmol; 1999 May; 83(5):632. PubMed ID: 10917687
    [No Abstract]   [Full Text] [Related]  

  • 20. Corneal thickness differences between sexes after oxybuprocaine eye drops.
    Fernandez-Garcia P; Cerviño A; Quiles-Guiñau L; Albarran-Diego C; Garcia-Lazaro S; Sanchis-Gimeno JA
    Optom Vis Sci; 2015 Jan; 92(1):89-94. PubMed ID: 25360701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.